Remedent, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a REMI research report →
Price Chart
About the company
Remedent, Inc. , operating through its various subsidiaries, specializes in the research, development, manufacturing, and distribution of products for both oral hygiene and aesthetic dentistry. The company's core offerings include professional-grade dental veneers and teeth whitening systems, designed for use by dental practitioners as well as for over-the-counter purchase by consumers.
- CEO
- Guy De Vreese
- IPO
- 2006
- Employees
- 3
- HQ
- Gent, VL, BE
Get TickerSpark's AI analysis on REMI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $14.00K
- P/E
- -0.05
- PEG
- -0.00
- P/S
- 0.01
- P/B
- 0.01
- EV/EBITDA
- 0.06
- Div Yield
- 0.00%
- Gross Margin
- 61.17%
- Op Margin
- -12.46%
- Net Margin
- -27.83%
- ROE
- -11.26%
- ROIC
- -4.99%
Latest fiscal year · YoY change
- Revenue
- $986.22K+14.2%
- Gross Profit
- $603.24K+19.3%
- Op Income
- $-122,890
- Net Income
- $-274,446+81.6%
- EPS
- $-0.01+81.7%
- OCF Growth
- -145.9%
- FCF Growth
- -145.9%
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -0.42
- RSI (14)
- 84
- Avg Volume
- 6.38K
No earnings-call transcripts are available for REMI yet.
- Free Float
- 63.7%
- Shares Outstanding
- 20.00M
- Float Shares
- 12.73M
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 2, 15 | Sternberg Stuart | buy | 399,819 |
| Dec 2, 15 | Sternberg Stuart | buy | 399,819 |
| Jul 24, 13 | Sternberg Stuart | other | 0 |
| Jul 24, 13 | MARXE AUSTIN W & GREENHOUSE DAVID M | sell | 2,848,408 |
| Jul 18, 13 | MARXE AUSTIN W & GREENHOUSE DAVID M | sell | 225,000 |
| Jul 19, 13 | MARXE AUSTIN W & GREENHOUSE DAVID M | sell | 165,000 |
| Jul 19, 13 | MARXE AUSTIN W & GREENHOUSE DAVID M | sell | 500 |
| Jul 16, 13 | MARXE AUSTIN W & GREENHOUSE DAVID M | sell | 713,025 |
| Nov 30, 12 | MARXE AUSTIN W & GREENHOUSE DAVID M | sell | 45,000 |
| Dec 3, 12 | MARXE AUSTIN W & GREENHOUSE DAVID M | sell | 200,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our REMI coverage
Recent articles, reports, and earnings notes.
No research on REMI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate REMI report →Reviewing Remedent (OTCMKTS:REMI) & Becton, Dickinson and Company (NYSE:BDX)
defenseworld.net · Jan 14
Reviewing Remedent (OTCMKTS:REMI) and Escalon Medical (OTCMKTS:ESMC)
defenseworld.net · Nov 25
Remedent (OTCMKTS:REMI) vs. Cooper Companies (NASDAQ:COO) Financial Analysis
defenseworld.net · Oct 26
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.